Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System
Novo Nordisk A/S (NYSE:NVO) has disclosed that it retains approximately 60% of the list price of its diabetes and obesity medications, Ozempic and Wegovy, in the U.S. after accounting for rebates and fees paid to intermediaries.